This resource provides unique primate reagents and services not available commercially in support of NIH funded investigators using nonhuman primates (NHP) as pre-clinical models for vaccine efficacy and immunotherapies. State of the art investigations of immune responses related to human infectious diseases, autoimmune diseases, organ and cell allogeneic and xenogeneic transplantation models or immunization procedures that use nonhuman primate models increasingly include the use of recombinant cytokines, chemokines, growth factors or immunomodulatory ligands in vivo. While the close evolutionary relationship between human and nonhuman primates results in cross reactivity between most human recombinant factors when used with NHP cells, differences in affinity/bioactivity have been noted. More important however, most NHP molecules are not identical to human homologues, often leading to the development of neutralizing antibody responses to the xenogeneic molecule in vivo, markedly restricting the repeated and most optimal in vivo use of select immunomodulators in these models. The ready availability of standardized purified recombinant NHP reagents has largely alleviated this limitation and allowed investigators to address seminal questions using NHP during the past 7 years of funding. In addition, testing of in vivo administration of these reagents has markedly revised the clinical administration schedule, leading to more tolerable and efficacious dosing. Thus, this application requests continued support for allowing this Resource to provide NHP factors, in DNA and protein form. Specifically, the resource will perform the following: 1. Continuation and expansion of preparation, testing and distribution of NHP cytokines/chemokines and soluble receptors in protein and recombinant DNA expression vectors. 2. Characterization and in vivo testing of soluble cytokine receptors as immune modulatory enhancers. 3. Generation of IgG and IgA Fc fusion molecules for differential targeting of cytokines to systemic vs. mucosal sites for enhanced localized immunomodulation. 4. Generation of polyclonal antibodies to NHP cytokines for which monoclonal antibodies are lacking.
(provided by applicant): The goals of this grant are to continue and to expand the services and reagents provided by this unique resource to investigators using nonhuman primates as preclinical models for human disease and (immuno) therapy. To validate the data in the monkey model, the use of monkey reagents rather than human ones are imperative to avoid bias introduced by the use of heterologous reagents. Hence the need for the proposed services and reagents
|Hong, Jung Joo; Amancha, Praveen K; Rogers, Kenneth A et al. (2014) Early lymphoid responses and germinal center formation correlate with lower viral load set points and better prognosis of simian immunodeficiency virus infection. J Immunol 193:797-806|
|Pallikkuth, Suresh; Micci, Luca; Ende, Zachary S et al. (2013) Maintenance of intestinal Th17 cells and reduced microbial translocation in SIV-infected rhesus macaques treated with interleukin (IL)-21. PLoS Pathog 9:e1003471|
|Watkins, Jennifer D; Sholukh, Anton M; Mukhtar, Muhammad M et al. (2013) Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS 27:F13-20|
|Amancha, Praveen K; Hong, Jung Joo; Rogers, Kenneth et al. (2013) In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4+ and CD8+ T cell responses but has limited clinical benefit. J Immunol 191:6060-70|
|Hong, Jung Joo; Amancha, Praveen K; Rogers, Kenneth et al. (2013) Re-evaluation of PD-1 expression by T cells as a marker for immune exhaustion during SIV infection. PLoS One 8:e60186|